Atrichia with Papular Lesions: Importance of Histology at an Early Disease Stage

We report the case of a 5-year-old girl born from consanguineous parents, presenting with alopecia universalis since the age of 8 months, without papules or cysts over the scalp or body. The goal of this paper is to emphasize the relevance of histopathology for the early diagnosis of atrichia with papular lesions in children with alopecia universalis, in settings where genetic testing may not be available.Skin Appendage Disord 2018;4:129-130
Source: Skin Appendage Disorders - Category: Dermatology Source Type: research

Related Links:

Ichthyosis with confetti (IWC) is a genodermatosis characterized by congenital erythroderma and the systematic development of epidermal pale spots not described in other genodermatoses. All IWC patients are carriers of a heterozygous keratin (KRT)10 or KRT1 variant leading to a shifted reading frame and the translation of an aberrant carboxyl (C)-terminus. The aberrant KRT10/KRT1 protein is localized in the nucleus instead of the cytoplasm. 20 years ago, 2 patients with an IWC-like phenotype were described to suffer from MAUIE (micropinnae, alopecia universalis, ichthyosis, ectropion) syndrome.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Genetics and Cell Based Therapy Source Type: research
CONCLUSIONS: This case suggests that alopecia areata may be a rare immune-related adverse event of immune checkpoint agents. Its late onset in our patient is uncommon and unexpected, underlining that the risk of nivolumab-induced toxicity is not limited to the beginning of treatment. Despite its rarity, alopecia areata should be considered in the range of adverse events potentially induced by immune checkpoint inhibitors even in the long term. Potential association between toxicity and efficacy of immunotherapy in NSCLC warrants further investigation. PMID: 31456503 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Background: Alopecia areata (AA) is a chronic disorder characterized by patchy loss of hair. Sometimes disease can be severe leading to loss of entire scalp and body hair. Management of these patients is very difficult with the available options of topical and systemic immunosuppressant agents. Tofacitinib, JAK3 inhibitor, is emerging as a promising drug for the management of severe and resistant cases of AA/totalis/universalis.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Background: The psychological effects of alopecia can be massive. Alopecia is associated with a greater risk of anxiety and depression. Patients with alopecia universalis have a
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Renu KandpalInternational Journal of Trichology 2019 11(4):173-176 Alopecia universalis (AU) is a condition which causes generalized hair loss of the body. It is postulated that autoimmunity plays an important role in its pathogenesis. It is characterized by the involvement of multiple inflammatory cytokines such as tumor necrosis factor-alpha and multiple interferons. Hence, biologics like tumor necrosis factor alpha (TNF-α) antagonist may be used to block this inflammatory process. It is not very commonly appreciated that the use of biologics can lead to alopecia areata. Here, we report a case of severe alopecia ar...
Source: International Journal of Trichology - Category: Dermatology Authors: Source Type: research
Alopecia areata (AA) is a common, autoimmune, alopecia with heterogeneous severity and distribution. Previous studies found conflicting results about AA epidemiology.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31361044 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Conditions:   Alopecia Areata;   Alopecia Totalis;   Alopecia Universalis Intervention:   Combination Product: Stem Cell Educator therapy combined with minoxidil Sponsors:   Tianhe Stem Cell Biotechnologies Inc.;   Yale University;   Hackensack Meridian Health Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
PMID: 31145072 [PubMed - in process]
Source: Skinmed - Category: Dermatology Authors: Tags: Skinmed Source Type: research
This article is protected by copyright. All rights reserved. PMID: 31102412 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
More News: Alopecia | Alopecia Universalis | Children | Dermatology | Genetics | Girls | Skin